1.37Open1.37Pre Close0 Volume262 Open Interest12.50Strike Price0.00Turnover162.96%IV2.54%PremiumOct 18, 2024Expiry Date1.08Intrinsic Value100Multiplier1DDays to Expiry0.29Extrinsic Value100Contract SizeAmericanOptions Type-0.8504Delta0.2441Gamma9.93Leverage Ratio-0.1138Theta-0.0003Rho-8.44Eff Leverage0.0014Vega
Biomea Fusion Stock Discussion
trigger sold 1/4 during while market shaky
hope the diabetes study outcome rocket
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials of BMF-219, an investigational covalent menin inhibitor, for type 2 and type 1 diabetes(COVALENT-111 and COVALENT-112).
The company's CEO, Thomas Butler, expressed confidence in BMF-219 as a novel, first-in-class agent for diabetes treatment, noting that safety concern...
No comment yet